论文部分内容阅读
目的：研究丙氨瑞林作用于子宫内膜癌后ｒａｓ、ｍｙｃ及Ｐ５３基因蛋白的变化，探讨其治疗子宫内膜癌的机理。方法：对１９例经诊断性刮宫后病理确诊的子宫内膜癌病人，予丙氨瑞林２００μｇ肌注，每日１次，共７天，用药结束３天后手术。对病人用药前诊刮标本及用药后子宫标本癌组织作免疫组化（ＡＢＣ法）染色，观察ｒａｓ、ｍｙｃ及Ｐ５３基因的表达。结果：用药后ｒａｓ、ｍｙｃ阳性级别较用药前下降（Ｐ＜０．０５），而这种变化与病人年龄、月经状况、临床期别、组织病理亚型及癌周内膜无关（Ｐ＞０．０５）；用药前后Ｐ５３基因表达变化不明显。结论：丙氨瑞林可能通过影响子宫内膜癌相关癌基因来抑制子宫内膜癌的生长。
Objective: To study the changes of ras, myc and p53 gene proteins in endometrial carcinoma treated by ararelin and explore the mechanism of endometrial cancer. Methods: Nineteen patients with endometrial carcinoma confirmed by pathological diagnosis after curettage were given intramuscular injection of 200 μg of avermectin once daily for 7 days. The operation was finished 3 days after the end of treatment. The patients were diagnosed by using the scrape specimen and the uterine cancer tissue after treatment with immunohistochemistry (ABC method) to observe the expressions of ras, myc and P53 genes. Results: The positive rates of ras and myc in the ras were lower than those before treatment (P <0.05), but the changes were not related to the age, menstrual status, clinical stage, histopathological subtypes and endometrial cancer (P> 0.05) .05); P53 gene expression before and after treatment did not change significantly. Conclusions: Alarelin may inhibit the growth of endometrial carcinoma by affecting the expression of oncogene related oncogene.